On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

CannabisNewsBreaks – CV Sciences, Inc. (CVSI) Mines the Benefits of Science and Nature to Build Cannabidiol-Based Portfolio

Company: CV Sciences, Inc. (CVSI)
Category: Stock Spotlights

The strategic integration of science and nature is the cornerstone of operations at CV Sciences (OTCQB: CVSI). Its Pharmaceuticals Division, for example, is developing synthetically formulated cannabidiol (CBD)‐based medicine for which the company is pursuing FDA approval. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for the treatment of a range of medical conditions. The company’s initial drug candidate (CVSI-007) is a chewing gum containing nicotine and synthetic CBD to support cessation of smokeless tobacco use and addiction. Focusing on enhancing the quality of life, CV Sciences’ Consumer Products Division delivers botanical-based CBD products such as PlusCBD Oil™, the top-selling brand of hemp-derived CBD; and Purified Liquids™ CBD vape blends. Each brand undergoes a formal safety review and is backed by case reports and physician recommendations.

To learn more visit www.cvsciences.com

About CV Sciences, Inc.

CV Sciences, Inc. (OTCBB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing, and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada, and San Diego, California.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of CannabisNewsWire (CNW). NNB keeps you up-to-date on active US Public Companies complementary to CNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, CNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information, visit https://www.CannabisNewsWire.com.

Please see full disclaimers on the CannabisNewsWire website: http://nnw.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722